DOPHEN BIOMED, INC.

Biotech · Private

Engineered microbial transglutaminase enzyme for site-specific conjugation of cytotoxic drugs to antibodies, producing homogeneous antibody-drug conjugates (ADCs)

Grants
$150K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel enzymatic site-specific antibody drug conjugation technique to produce homogeneous antibody drug conjugate (ADC)s with improved safety, stability and efficacy$149,625
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1639Atalanta Therapeutics——
1640Aera Therapeutics——
1641LIGANDOMICSRX, LLC——
1642DOPHEN BIOMED, INC.——
1643T3S Technologies, Inc.——
1644MIDI, INC.——
1645CANCER TARGETED TECHNOLOGY, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.